首页> 外文期刊>Journal of clinical sleep medicine: JCSM : official publication of the American Academy of Sleep Medicine >Non-24-Hour Sleep-Wake Disorder in Sighted Patients: Dealing With an Orphan Disease
【24h】

Non-24-Hour Sleep-Wake Disorder in Sighted Patients: Dealing With an Orphan Disease

机译:视力患者的非24小时睡眠/觉醒障碍:应对孤儿疾病

获取原文
           

摘要

We read with interest the work by Malkani et al., who emphasize the difficulties that can be met in everyday clinical practice by diagnosing and treating non-24-hour sleep-wake disorder (N24SWD), especially in sighted subjects.1 In fact, while this condition has been early investigated in totally blind people, given its high prevalence and its intuitive pathophysiology (lack of light perception to entrain circadian rhythms), leading some authors to define it the quintessential circadian rhythm disorder,2 less attention has been dedicated to the study of sighted patients.Apart from the pioneering temporal isolation studies conducted in natural bunkers, where healthy volunteers showed a free-running rhythm after deprivation of fundamental time cues, such as daylight, clinical cases of sighted individuals, who spontaneously develop N24SWD have been considered extremely rare. However, reports of similar, sporadic cases are growing in the literature, including some recently published in the Journal of Clinical Sleep Medicine35 prior to the case series by Malkani et al.1 Thus, while the epidemiology of sighted N24SWD remains overall unknown, its prevalence may have been underestimated so far, especially since the correct diagnosis is often overlooked.Secondarily, while specific clock genes have been associated with some circadian rhythm sleep-wake disorders, the molecular mechanisms underlying N24SWD, by lacking familial clusters, are unexplored. Therefore, genome-wide association studies may contribute to better understand the role of genetics,6 eg, regarding a possible predisposition to disease or response to treatment.Finally, although the combination of light and melatonin represents the best available therapeutic strategy for sighted N24SWD, circadian rhythm resynchronization is not always achieved. No randomized controlled trials have been conducted so far, and the sole pharmacologic agent on the market (Tasimelteon) is only approved for use in blind patients.In conclusion, when considering N24SWD in sighted subjects, we are confronted with an orphan disease, listed on the European online portal Orphanet (https://www.orpha.net), and which is not only rare and underinvestigated, but also commercially rather unattractive. This condition has nevertheless dramatic consequences for the affected people, due to the severe circadian misalignment, going from the inability to work at regular times, to social isolation, as well as physical and mental disorders.At our institution, we are collecting clinical cases of N24SWD diagnosed in Switzerland in a database, with the aim to create an international registry of patients assessed worldwide through standardized and comparable methods. This may represent a pivotal step forward to reach further scientific evidence and knowledge about the disorder, moving from the description of individual cases using different tools, to a shared data repository that will help us to better understand the patho-physiology, epidemiology and treatment of sighted N24SWD.DISCLOSURE STATEMENTThis work was performed at the Centre for Chronobiology, University of Basel. The author reports no conflicts of interest.
机译:我们感兴趣地阅读了Malkani等人的工作,他们强调了通过诊断和治疗非24小时睡眠-觉醒障碍(N24SWD),尤其是在有视力的受试者中,可以在日常临床实践中遇到的困难。1实际上,尽管这种情况已经在全盲人中进行了早期调查,但由于这种疾病的患病率很高且具有直观的病理生理学(缺乏光感来吸引昼夜节律),因此导致一些作者将其定义为典型的昼夜节律障碍2,而对这种情况的关注较少除了在自然掩体中进行的开创性的时间隔离研究之外,健康的志愿者在缺乏基本时间线索(如日光)后表现出自由奔放的节律,自发发展为N24SWD的有眼力个体的临床病例被认为极为罕见。然而,文献报道中出现了类似的,零星病例的报道,包括最近在Malkani等人的病例系列之前发表于《临床睡眠医学杂志》 35上的一些报道。因此,尽管有目睹的N24SWD的流行病学仍然未知,但其流行程度第二,虽然特定的时钟基因与一些昼夜节律性睡眠-唤醒障碍有关,但由于缺乏家族簇,N24SWD的分子机制尚待探索。因此,全基因组关联研究可能有助于更好地了解遗传学的作用6,例如关于疾病的易感性或对治疗的反应。最后,尽管光和褪黑激素的组合代表了有眼力的N24SWD的最佳可用治疗策略,昼夜节律重新同步并不总是可以实现的。迄今为止,尚未进行任何随机对照试验,并且市场上唯一的药理药物(Tasimelteon)仅获准用于盲人患者。总之,当在有视力的受试者中考虑使用N24SWD时,我们面临一种孤儿疾病,该疾病列于欧洲在线门户网站Orphanet(https://www.orpha.net),它不仅罕见且研究不足,而且在商业上也没有吸引力。由于严重的昼夜节律紊乱,从无法正常工作,社交孤立,以及身体和精神障碍,这种情况仍然给受影响的人们带来巨大后果。在我们的机构中​​,我们正在收集以下病例的临床病例: N24SWD在瑞士的数据库中进行了诊断,目的是建立一个通过标准化和可比较的方法对全世界评估的患者进行国际注册的方法。从使用不同工具对个别病例进行描述到共享数据存储库,这可能是迈向进一步获取有关该疾病的科学证据和知识的关键性一步,这将有助于我们更好地了解该疾病的病理生理,流行病学和治疗方法N24SWD。披露声明这项工作是在巴塞尔大学计时生物学中心进行的。作者报告没有利益冲突。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号